EP1448157A1 - Preparation cosmetique et/ou dermatologique contenant de l'acide dicarboxylique d'octadecene et des substances filtrant les u.v. - Google Patents

Preparation cosmetique et/ou dermatologique contenant de l'acide dicarboxylique d'octadecene et des substances filtrant les u.v.

Info

Publication number
EP1448157A1
EP1448157A1 EP02802642A EP02802642A EP1448157A1 EP 1448157 A1 EP1448157 A1 EP 1448157A1 EP 02802642 A EP02802642 A EP 02802642A EP 02802642 A EP02802642 A EP 02802642A EP 1448157 A1 EP1448157 A1 EP 1448157A1
Authority
EP
European Patent Office
Prior art keywords
cosmetic
acid
preparations
filter
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02802642A
Other languages
German (de)
English (en)
Inventor
Anja Göppel
Claudia Mundt
Jens Schulz
Rainer Wolber
Thomas Blatt
Reza Keyhani
Christoph Smuda
Franz STÄB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001155961 external-priority patent/DE10155961A1/de
Priority claimed from DE2001155959 external-priority patent/DE10155959A1/de
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1448157A1 publication Critical patent/EP1448157A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/08—Preparations for bleaching the hair

Definitions

  • the present invention relates to the use of active ingredients known per se for cosmetic and topical dermatological skin lightening or for preventing skin tanning, in particular skin tanning caused by UV radiation, and for lightening the natural hair color.
  • the present invention relates to cosmetic and dermatological preparations for the prophylaxis and treatment of cosmetic or dermatological skin changes such as e.g. unwanted pigmentation, e.g. local hyper- and deficient pigmentation (e.g. liver spots, freckles), inhibition of natural pigmentation, but also for purely cosmetic lightening of larger areas of the skin, which are pigmented to suit the individual skin type.
  • unwanted pigmentation e.g. local hyper- and deficient pigmentation (e.g. liver spots, freckles)
  • inhibition of natural pigmentation e.g. e.g. liver spots, freckles
  • purely cosmetic lightening of larger areas of the skin which are pigmented to suit the individual skin type.
  • Melanocytes are responsible for the pigmentation of the skin. They are found in the lowest layer of the epidermis, the stratum basale, next to the basal cells as - depending on the skin type, either isolated or more or less frequently occurring pigment-forming cells. As characteristic cell organelles, melanocytes contain melanosomes, in which the melanin is formed. When stimulated by UV radiation, among other things, melanin is increasingly formed. This is ultimately transported via the living layers of the epidermis (keratinocytes) into the horny layer (comeocytes) and causes a more or less pronounced brown to brown-black skin color.
  • DHICA and DHI melanin brown to brown-black eumelanins
  • DHICA and DHI melanin are produced via the common intermediate stages dopaquinone and dopachrome. The latter will, partly with participation further enzymes, either in indole-5,6-quinone carboxylic acid or in indole-5,6-quinone, from which the two eumelanins mentioned arise.
  • the formation of phaeomelanin occurs, among other things, via the intermediates dopaquinone and cysteinyldopa.
  • melanin-producing melanocytes are also responsible for the hair color (pigmentation of the hair).
  • the amount and composition of " melanin in the hair determines the natural hair color, which is genetically determined.
  • UV radiation e.g. freckles, ephelides
  • genetic disposition e.g. incorrect pigmentation of the skin during wound healing or scarring or skin aging (e.g. Lentigines seniles).
  • the object of the present invention was to remedy this problem.
  • 8-Hexadecen-1, 16-dicarboxylic acid (dioic acid, CAS number 20701-68-2; provisional INCI name Octadecendioic acid) is a metabolite of yeast cells of the Candida strain. It is characterized by the following structure:
  • COOH A fatty acid of purely vegetable origin serves as the starting substance. This is converted into the hydroxy fatty acid, which is then oxidized to the fatty acid aldehyde and ultimately to the dicarboxy acid.
  • the yeast cells come from selected mutant strains.
  • the commercial product has a purity of 95%. 8-Hexadecen-1, 16-dicarboxylic acid is present as a mixture of the cis and trans isomers, the cis isomer predominating in terms of quantity.
  • Oleic acid can be contained in the product at a concentration of approximately 3%.
  • UV protection substances are used in cosmetic preparations to protect the skin from sunlight and the damage to the skin caused thereby.
  • These are inorganic pigments, UV-A, UV-B and / or broadband filter substances.
  • R 1 and R 2 independently of one another are hydrogen, CC 20 alkyl, C 3 -C 10 cycloalkyl or C 3 - do-cycloalkenyl, the substituents R 1 and R 2 together with the nitrogen atom to which they are bonded 5- or 6-ring can form and
  • R 3 represents a CC 20 alkyl radical.
  • % based in each case on the total weight of the preparations, and 8-hexadecen-1,16-dicarboxylic acid in a total concentration of 0.001-10% by weight, preferably 0.005-8% by weight, in particular 0.05-5% by weight. -% based on the total weight of the preparations.
  • a hydroxybenzophenone is used as the UV filter substance. It is further preferred if the hydroxybenzophenone is 2- (4 '- (diethylamino) -2'-hydoxybenzoyl) - benzoic acid hexyl ester, which is represented by the chemical structural formula
  • the content of one or more hydroxybenzophenones is from 0.1 to 20% by weight, preferably 0.1 to 15% by weight, particularly preferably 0.1 to 10% by weight, in each case on the total weight of the preparations.
  • the preparations contain at least one further UV filter substance, selected from the group consisting of triazines, benzotriazoles, the UV filter which is liquid at room temperature and organic and / or inorganic pigments, and are preferred as further UV-A -Filter substance and / or broadband filter dibenzoylmethane derivatives [in particular the 4- (tert-butyl) -4'-methoxydibenzoylmethane], phenylene-1, 4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt, 1,4-di (2-oxo-10-sulfo-3-bornylidene-methyl) -benzene and its salts and 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2 -hydroxy] -phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine,
  • the invention also includes the use of such cosmetic or dermatological preparations against unwanted pigmentation of the skin and / or for the treatment of pigmentation disorders. Furthermore, the undesirable pigmentation of the hair is reduced by the combination of active ingredients mentioned and thus brings about a brightening of the hair.
  • active ingredient combination The combination of 8-hexadecen-1, 16-dicarboxylic acid and UV filters, hereinafter referred to as “active ingredient combination according to the invention”, has proven to be extremely effective against undesired pigmentation, in particular local hyperpigmentation, and against skin tanning caused by UV radiation, specifically both preventively and in the sense of a treatment, but it is also extremely advantageous according to the invention to use the active substance combination or cosmetic or topical dermatological preparations according to the invention with an effective content of active substance combination used according to the invention for the cosmetic or dermatological treatment of undesired skin pigmentation, ie for example inhomogeneous pigmentation aging skin, lentigines senile or postinflammatory hyperpigmentation.
  • undesired skin pigmentation ie for example inhomogeneous pigmentation aging skin, lentigines senile or postinflammatory hyperpigmentation.
  • the prophylaxis or the cosmetic or dermatological treatment with the active ingredient combination used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of active ingredient combination used according to the invention is carried out in the usual way, in such a way that the active ingredient combination according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient combination used according to the invention is applied to the affected skin areas.
  • the active substance combination according to the invention fulfills the objects on which the invention is based.
  • the active ingredient combination according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be in various forms. So you can e.g.
  • a solution an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick, a transdermal therapeutic system or an aerosol.
  • Emulsions according to the invention in the sense of the present invention are advantageous and contain, for example, fats, oils, Waxes and / or other fat bodies, as well as water and one or more emulsifiers, as are usually used for such a type of formulation.
  • the active ingredient 8-hexadecene-1, 16-dicarboxylic acid is also advantageous to be used in the form of molecular adducts of 'cyclodextrins. It is believed that the cyclodextrin skeletons act as the host molecule and 8-hexadecen-1, 16-dicarboxylic acid as the guest molecule.
  • cyclodextrins are dissolved in water and 8-hexadecen-1, 16-dicarboxylic acid is added. The molecular adduct then precipitates as a solid and can be subjected to the usual cleaning and preparation steps.
  • Medical topical compositions in the sense of the present invention generally contain one or more medicaments in an effective concentration.
  • cosmetic or topical dermatological compositions within the meaning of the present invention, depending on their structure, can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nutritional cream, day or night cream, etc. It may be possible and advantageous to use the compositions according to the invention as a basis for pharmaceuticals Use wording.
  • cosmetic and dermatological preparations the main purpose of which is not to protect against sunlight, but which nevertheless contain other UV protection substances.
  • So z. B. usually incorporated into day creams or makeup products UV-A or UV-B filter substances.
  • UV protection substances like antioxidants and, if desired, preservatives, also effectively protect the preparations themselves against spoilage.
  • Cosmetic and dermatological preparations which are in the form of a sunscreen are also favorable.
  • the preparations in the sense of the present invention preferably contain at least one further UV-A, UV-B and / or broadband filter substance.
  • the formulations may, although not necessary, optionally also contain one or more organic and / or inorganic pigments as UV filter substances, which may be present in the water and / or the oil phase.
  • the preparations according to the invention can also advantageously be in the form of so-called oil-free cosmetic or dermatological emulsions which contain a water phase and at least one UV filter substance which is liquid at room temperature as a further phase.
  • Preferred inorganic pigments are metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular oxides of titanium (TiO 2 ), zinc (ZnO), iron (e.g. Fe 2 O 3 ), zirconium (ZrO 2 ), silicon ( SiO 2 ), manganese (e.g. MnO), aluminum (Al 2 O 3 ), cerium (e.g. Ce 2 0 3 ), mixed oxides of the corresponding metals as well as mixtures of such oxides and the sulfate of barium (BaS0 4 ).
  • the pigments can also advantageously be used in the form of commercially available oily or aqueous predispersions. Dispersing aids and / or solubilizing agents can advantageously be added to these pre-dispersions.
  • the pigments can advantageously have been surface-treated (“coated”), for example a hydrophilic, amphiphilic or hydrophobic character should be formed or retained.
  • This surface treatment can consist in that the pigments are prepared using a thin method using methods known per se hydrophilic and / or hydrophobic inorganic and / or organic layer
  • the various surface coatings can also contain water in the sense of the present invention.
  • Inorganic surface coatings in the sense of the present invention can consist of aluminum oxide (Al 2 O 3 ), aluminum hydroxide Al (OH) 3 , or aluminum oxide hydrate (also: alumina, CAS no .: 1333-84-2), sodium hexametaphosphate (NaP0 3 ) 6 , sodium metaphosphate (NaPO 3 ) n , silicon dioxide (SiO 2 ) (also: silica, CAS No .: 7631-86-9), or iron oxide (Fe 2 O 3 ).
  • Al 2 O 3 aluminum oxide
  • Al (OH) 3 aluminum hydroxide Al
  • aluminum oxide hydrate also: alumina, CAS no .: 1333-84-2
  • sodium hexametaphosphate (NaP0 3 ) 6 sodium metaphosphate (NaPO 3 ) n
  • silicon dioxide (SiO 2 ) also: silica, CAS No .: 7631-86-9
  • iron oxide Fe 2 O 3
  • Organic surface coatings in the sense of the present invention can consist of vegetable or animal aluminum stearate, vegetable or animal stearic acid, lauric acid, dimethylpolysiloxane (also: dimethicone), methylpolysiloxane (methicone), simethicone (a mixture of dimethylpolysiloxane with an average chain length of 200 to 350 Dimethylsiloxane units and silica gel) or alginic acid.
  • These organic surface coatings can occur alone, in combination and / or in combination with inorganic coating materials.
  • Zinc oxide particles and predispersions of zinc oxide particles suitable according to the invention are available under the following trade names from the companies listed:
  • Suitable titanium dioxide particles and predispersions of titanium dioxide particles are available under the following trade names from the companies listed:
  • UV-A filter substances for the purposes of the present invention are dibenzoylmethane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS-Nr. 70356- 09-1) carried by Givaudan under the trade name Parsol ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • dibenzoylmethane derivatives in particular 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS-Nr. 70356- 09-1) carried by Givaudan under the trade name Parsol ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • UV filter substances in the sense of the present invention are sulfonated, water-soluble UV filters, such as. B .:
  • Benzene-1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid) has the INCI name Terephtalidene Dicampher Sulfonic Acid (CAS. No .: 90457-82-2) and is, for example, under the trade name Mexoryl SX from from the company
  • Sulfonic acid derivatives of 3-benzylidene camphor such as. B. 4- (2-oxo-3-bornylidene methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidene methyl) sulfonic acid and salts thereof.
  • Advantageous UV filter substances in the sense of the present invention are also so-called broadband filters, i.e. Filter substances that absorb both UV-A and UV-B radiation.
  • Advantageous broadband filters or UV-B filter substances are, for example, triazine derivatives, such as, for. B.
  • Diethylhexylbutylamidotriazon (INCI: Diethylhexylbutamidotriazone), which is available under the trade name UVASORB HEB from Sigma 3V;
  • An advantageous broadband filter in the sense of the present invention is also the 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol), which is available under the trade name Tinosorb® M from CIBA-Chemicals GmbH.
  • Another advantageous broadband filter for the purposes of the present invention is 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1- [(trimethylsilyl) oxy] disiloxanyl] propyl] - phenol (CAS no .: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is available under the trade name Mexoryl® XL from Chimex.
  • the other UV filter substances can be oil-soluble or water-soluble.
  • Advantageous oil-soluble UV-B and / or broadband filter substances in the sense of the present invention are e.g. B .:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone
  • Advantageous water-soluble filter substances are e.g. B .:
  • Sulfonic acid derivatives of 3-benzylidene camphor such as. B. 4- (2-oxo-3-bornylidene methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene methyl) sulfonic acid and their salts.
  • a further light protection filter substance according to the invention to be used advantageously is ethylhexyl-2-cyano-3,3-diphenylacrylate, obtainable (octocrylene) from BASF under the name Uvinul ® N 539th
  • Particularly advantageous preparations within the meaning of the present invention which are distinguished by a high or very high UV-A and / or UV-B protection, preferably also contain further UV-A and in addition to the filter substance (s) according to the invention / or broadband filter, especially dibenzoylmethane derivatives [for example the 4- (tert-butyl) -4'-meth-oxydibenzoylmethane], phenylene-1,4, bis (2-benzimidazyl) -3,3'-5,5'- tetrasulfonic acid and / or its salts, the 1,4-di (2-oxo-10-sulfo-3-bomylidenemethyl) benzene and / or its salts and / or the 2,4-bis - ⁇ [4- (2- Ethyl-hexyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine, in each case individually or in any
  • the preparations according to the invention advantageously contain the substances which absorb UV radiation in the UV-A and / or UV-B range in a total amount of, for. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1, 0 to 15.0 wt .-%, each based on the total weight of the preparations to cosmetic To provide preparations that protect the hair or skin from the entire range of ultraviolet radiation.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic active ingredients, auxiliaries and / or additives as are usually used in such preparations, e.g. Antioxidants, preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic active ingredients e.g. Antioxidants, preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic
  • the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-camosine, D-camosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ß-carotene, lycopene) and their derivatives, retinoids such as retinol, retinal and / or retinoic acid and the respective esters, ⁇ -lipoic acid and their derivatives (e.g.
  • amino acids eg glycine, histidine, tyrosine, tryptophan
  • imidazoles eg urocanic acid
  • peptides such as D, L-camosine, D-camosine, L-carnosine
  • Dihydrolipoic acid Dihydrolipoic acid
  • aurothioglucose propylthiouracil and other thiols '
  • thiols ' e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl -, Oleyl, ⁇ -linoleyl, cholesterol and glyceryl esters
  • dilauryl thiodipropionate distearyl thiodipropionate
  • thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthioninsulfox imines homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, heptathionine sulfoximine
  • very low tolerable doses e.g. pmol to ⁇ mol / kg
  • metal chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin
  • ⁇ - hydroxy acids e.g.
  • citric acid citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and its derivatives 2-aminopropionic acid diacetic acid, flavonoids, polyphenols, catechins, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g.
  • vitamin E acetate vitamin E acetate
  • benziferyl benzoate as well as coniferyl benzoate and their derivatives
  • ferulic acid and their derivatives butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybu tyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnS ⁇ 4) selenium and its
  • Derivatives e.g. selenium methionine
  • stilbenes and their derivatives e.g. stilbene oxide, trans-stilbene oxide
  • derivatives suitable according to the invention salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 0.1-10% by weight, based on the total weight the preparation. If vitamin E and / or its derivatives represent the antioxidant (s), it is advantageous to choose their respective concentrations from the range of 0.001-10% by weight, based on the total weight of the formulation.
  • the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, the following can be used as solvents:
  • Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or
  • Glycerin or esters of fatty alcohols with low C number alkanoic acids or with fatty acids
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or - monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether,
  • Water can also be a component of alcoholic solvents.
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions for the purposes of the present invention is advantageously selected from the group of esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C atoms, from the group of esters from aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononanoate, 2-ethylhexyl ethylhexyl palmitate stearate, 2-octyIdodecyIpalmitat, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate as well as synthetic, semi-synthetic and natural mixtures of such esters, eg jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, in particular the triglycerol esters, saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous, if appropriate, to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is advantageously selected from the group 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 2-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
  • C 12 are particularly advantageous. 15 alkylbenzoate and 2-ethylhexyl isostearate, mixtures of C ⁇ 2 . 15 alkylbenzoate and isotridecyl isononanoate and mixtures of C 12-15 alkylbenzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
  • Advantageous oil components are also e.g. B. butyl octyl salicylate (for example that available under the Hallbrite BHB trade name from CP Hall), hexadecyl benzoate and butyl octyl benzoate and mixtures thereof (Hallstar AB) and / or diethyl hexyl naphthalate (Hallbrite TQ).
  • B. butyl octyl salicylate for example that available under the Hallbrite BHB trade name from CP Hall
  • hexadecyl benzoate and butyl octyl benzoate and mixtures thereof Hallstar AB
  • Hallbrite TQ diethyl hexyl naphthalate
  • the oil phase can advantageously also contain cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Cyclomethicone (octamethylcyclotetrasiloxane) is advantageously used as the silicone oil to be used according to the invention.
  • silicone oils are also advantageous in the sense of to use the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • Gels used in the present invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickening agent which is preferably silicon dioxide or an aluminum silicate in the case of oily alcoholic gels and preferably a polyacrylate in the case of aqueous alcoholic or alcoholic gels.
  • a thickening agent which is preferably silicon dioxide or an aluminum silicate in the case of oily alcoholic gels and preferably a polyacrylate in the case of aqueous alcoholic or alcoholic gels.
  • Fixed pens contain e.g. natural or synthetic waxes, fatty alcohols or fatty acid esters. Lip care sticks and stick formulations for body deodorization are preferably used.
  • liquid oils for example paraffin oils, castor oil, isopropyl myristate
  • semi-solid components for example petroleum jelly, lanolin
  • solid components for example beeswax, ceresin and microcrystallines
  • Waxes or ozokerite high-melting waxes (e.g. carnauba wax, candelilla wax).
  • Suitable blowing agents for cosmetic and / or dermatological preparations sprayable from aerosol containers for the purposes of the present invention are the customary known volatile, liquefied blowing agents, for example hydrocarbons (propane, butane, isobutane), which can be used alone or as a mixture with one another. Compressed air can also be used advantageously.
  • hydrocarbons propane, butane, isobutane
  • Cosmetic preparations in the sense of the present invention can also be in the form of gels which, in addition to an effective content of the active ingredient according to the invention and solvents normally used for this purpose, preferably water, and also organic thickeners, eg gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, eg. B. aluminum silicates such as bentonite, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • the thickener is contained in the gel, for example, in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
  • aminobenzophenone is to be understood as meaning the hexyl 2- (4 '- (diethylamino) -2'-hydoxybenzoyl) benzoate.
  • the pH is adjusted to 6.
  • the pH is adjusted to 6.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des préparations cosmétiques ou dermatologiques comportant des substances filtrant les U.V., en combinaison avec de l'acide 8-hexadécène-1,16-dicarboxylique.
EP02802642A 2001-11-09 2002-11-04 Preparation cosmetique et/ou dermatologique contenant de l'acide dicarboxylique d'octadecene et des substances filtrant les u.v. Ceased EP1448157A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10155961 2001-11-09
DE2001155961 DE10155961A1 (de) 2001-11-09 2001-11-09 Kosmetische und/oder dermatologische Wirkstoffkombination
DE2001155959 DE10155959A1 (de) 2001-11-09 2001-11-09 Kosmetische und/oder dermatologische Wirkstoffkombination
DE10155959 2001-11-09
PCT/EP2002/012267 WO2003039502A1 (fr) 2001-11-09 2002-11-04 Preparation cosmetique et/ou dermatologique contenant de l'acide dicarboxylique d'octadecene et des substances filtrant les u.v.

Publications (1)

Publication Number Publication Date
EP1448157A1 true EP1448157A1 (fr) 2004-08-25

Family

ID=26010582

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02802642A Ceased EP1448157A1 (fr) 2001-11-09 2002-11-04 Preparation cosmetique et/ou dermatologique contenant de l'acide dicarboxylique d'octadecene et des substances filtrant les u.v.

Country Status (5)

Country Link
US (1) US20050019279A1 (fr)
EP (1) EP1448157A1 (fr)
JP (1) JP2005507946A (fr)
KR (1) KR20050043781A (fr)
WO (1) WO2003039502A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323412A1 (fr) 2001-12-07 2003-07-02 L'oreal Composition filtrante contenant un filtre du type dérivé du dibenzoylméthane et un dérivé de 2-hydroxybenzophénone aminosubstitué
EP1323413A1 (fr) 2001-12-07 2003-07-02 L'oreal Composition filtrante contenant un dérivé de 1,3,5-triazine, un dérivé du dibenzoylméthane, et un dérivé de 2-hydroxybenzophénone aminosubstitué

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8106094B2 (en) * 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) * 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US8431550B2 (en) * 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) * 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
FR2833164B1 (fr) * 2001-12-07 2004-07-16 Oreal Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations
DE10238449A1 (de) * 2002-08-22 2004-03-04 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitung
DE10328547A1 (de) * 2003-06-24 2005-01-13 Basf Ag Mischung bestehend aus einem UV-A- und einem UV-B-Filter
DE10348631A1 (de) * 2003-10-15 2005-05-12 Beiersdorf Ag Emulgatorarme Zubereitungen mit 8-Hexadecen-1, 16-dicarbonsäure
AU2004290893A1 (en) * 2003-10-29 2005-06-02 Johnson & Johnson Consumer France S.A.S. Compositions comprising soy products and dioic acids
US20080318825A1 (en) * 2004-11-24 2008-12-25 The Proctor & Gamble Company Hair Treatment Agent
US20070185038A1 (en) * 2005-09-30 2007-08-09 The Procter & Gamble Company Regulation of mammalian keratinous tissue using skin care actives
US20080008818A1 (en) * 2006-06-23 2008-01-10 Miri Seiberg Partially denatured whole soybean extracts and methods of use thereof
US20080089960A1 (en) * 2006-10-16 2008-04-17 Miri Seiberg Use of Legume Products for the Treatment and Prevention of Radiotherapy-Induced Skin Damage
DE102007005093A1 (de) * 2007-01-25 2008-07-31 Beiersdorf Ag Kosmetische Zubereitung gegen Hautpigmentierungen
DE102008018787A1 (de) * 2008-04-11 2009-10-15 Beiersdorf Ag Zubereitung für die Tagespflege
DE102008018786A1 (de) * 2008-04-11 2009-10-15 Beiersdorf Ag Getönte Zubereitung für die Tagespflege
KR101503923B1 (ko) * 2008-05-14 2015-03-19 주식회사 엘지생활건강 수중유형의 화장료 조성물
EP2157076A1 (fr) * 2008-08-21 2010-02-24 Cognis IP Management GmbH Procédé de fabrication de diesters d'acides alpha, oméga dicarboxyliques non saturés
WO2013121592A1 (fr) * 2012-02-14 2013-08-22 L'oreal Composition cosmétique et procédé de coloration et décoloration de fibres kératiniques humaines
DE102012210379A1 (de) * 2012-06-20 2013-12-24 Beiersdorf Ag Kosmetische und dermatologische Zubereitung enthaltend eine oder mehrere Substanz(en), die das Gen / Protein für den Rezeptor Endo180 modulieren
DE102013220352A1 (de) * 2013-10-09 2015-04-09 Henkel Ag & Co. Kgaa Kosmetisches oder dermatologisches Mittel zur Aufhellung und zur Vermeidung von Auftreten der Hautflecken
FR3024037B1 (fr) 2014-07-25 2018-03-02 Sederma Ingredient actif cosmetique ou dermatologique comprenant un melange d'acides dicarboxyliques gras insatures, compositions le comprenant et utilisations cosmetiques ou dermatologiques
KR102076932B1 (ko) * 2019-06-17 2020-02-12 연세대학교 산학협력단 옥타데센 또는 이의 염을 유효성분으로 포함하는 피부 미백용 조성물
WO2021237318A1 (fr) * 2020-05-29 2021-12-02 L'oreal Composition cosmétique comprenant de l'acide dioïque insaturé et ses utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1046391A2 (fr) * 1999-04-20 2000-10-25 Basf Aktiengesellschaft Usage d'hydroxybenzophénones aminosubstituées comme filtres UV photostables dans des préparations cosmétiques et pharmaceutiques
WO2003032941A2 (fr) * 2001-10-13 2003-04-24 Beiersdorf Ag Combinaison de principes actifs cosmetique et/ou dermatologique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR900002772A (ko) * 1988-08-26 1990-03-23 진나이 쓰네오 외용제
IL99291A (en) * 1991-08-23 1997-04-15 Fischer Pharma Ltd Cosmetic preparations
GB9220667D0 (en) * 1992-09-30 1992-11-11 Unilever Plc Improvements in or relating to dioic acids
GB9220670D0 (en) * 1992-09-30 1992-11-11 Unilever Plc Cosmetic composition
AU774383B2 (en) * 1999-07-12 2004-06-24 Ciba Specialty Chemicals Holding Inc. Use of mixtures of micropigments for preventing tanning and for lightening skin and hair
WO2001070190A2 (fr) * 2000-03-23 2001-09-27 Unilever Plc Compositions cosmetiques
DE10039783A1 (de) * 2000-08-16 2002-02-28 Cognis Deutschland Gmbh Kosmetische Zubereitungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1046391A2 (fr) * 1999-04-20 2000-10-25 Basf Aktiengesellschaft Usage d'hydroxybenzophénones aminosubstituées comme filtres UV photostables dans des préparations cosmétiques et pharmaceutiques
WO2003032941A2 (fr) * 2001-10-13 2003-04-24 Beiersdorf Ag Combinaison de principes actifs cosmetique et/ou dermatologique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03039502A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323412A1 (fr) 2001-12-07 2003-07-02 L'oreal Composition filtrante contenant un filtre du type dérivé du dibenzoylméthane et un dérivé de 2-hydroxybenzophénone aminosubstitué
EP1323413A1 (fr) 2001-12-07 2003-07-02 L'oreal Composition filtrante contenant un dérivé de 1,3,5-triazine, un dérivé du dibenzoylméthane, et un dérivé de 2-hydroxybenzophénone aminosubstitué

Also Published As

Publication number Publication date
WO2003039502A1 (fr) 2003-05-15
JP2005507946A (ja) 2005-03-24
KR20050043781A (ko) 2005-05-11
US20050019279A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2003039502A1 (fr) Preparation cosmetique et/ou dermatologique contenant de l'acide dicarboxylique d'octadecene et des substances filtrant les u.v.
EP1455744A2 (fr) Combinaison de principes actifs cosmetique et/ou dermatologique
JP5113755B2 (ja) ヒドロキシ脂肪酸を含む化粧品組成物
CH697386B1 (de) Haut- und/oder Haarmittel enthaltend Verbindungen zur Steigerung der Hautbräunung.
WO2004017935A1 (fr) Preparation cosmetique et/ou dermatologique contenant un acide dicarbonique octadecene et un agent eclaircissant
DE10048260A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
EP1476130B1 (fr) Utilisation de diols specifiques pour réduire la viscosité des compositions cosmétiques et/ou dermatologiques
DE19720339A1 (de) Wirkstoffe und Zubereitungen für die Hautaufhellung und zur Verhinderung der Hautbräunung
DE10305965A1 (de) Kosmetische und/oder dermatologische Zubereitung
DE10122342A1 (de) Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen
WO2005048970A1 (fr) Utilisation de lignanes dans des preparations cosmetiques ou dermatologiques
EP0826360B1 (fr) Utilisation des dérivés de dibenzoylmethane pour atteindre ou améliorer la solubilité des dérivés de triazine dans l'huile
DE102008015428A1 (de) Kühlende Zubereitungen für den humanen Haut- und/oder Schleimhautkontakt mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid
DE10212865B4 (de) Verwendung von 9-Retinal-alkanolamin Schiffsche Base in kosmetischen der dermatologischen Formulierungen
DE10120315A1 (de) Verwendung von Klee-Extrakt in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe gegen und Behandlung von degenerativen Hauterscheinungen
DE10150734A1 (de) Kosmetische und/oder dermatologische Zubereitung
DE10155959A1 (de) Kosmetische und/oder dermatologische Wirkstoffkombination
DE10150731A1 (de) Wirkstoffkombination zur Verhinderung unerwünschter Hautpigmentierung
EP1834630A1 (fr) Préparations cosmétiques ou dermatologiques contenant de la glycyrrhétine et/ou de la glycyrrhizine et du 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phényl}-6-(4-methoxyphenyl)-1,3,5-triazin
DE10150742A1 (de) Wirkstoffkombination zur Verhinderung unerwünschter Hautpigmentierung
DE10150732A1 (de) Wirkstoffkombination zur Verhinderung unerwünschter Hautpigmentierung
DE10306452A1 (de) Neue Aminosäurederivate
DE10150735A1 (de) Wirkstoffkombination zur Verhinderung unerwünschter Hautpigmentierung
DE10163786A1 (de) Kosmetische und/oder dermatologische Wirkstoffkombination
DE10249271A1 (de) Neue Aminosäurederivate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

17Q First examination report despatched

Effective date: 20070719

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120823